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Abstract
Decision makers sometimes request information on the cost savings, cost-effectiveness, or cost-
benefit of public health programs. In practice, quantifying the health and economic benefits of 
population-level screening programs such as newborn screening (NBS) is challenging. It requires 
that one specify the frequencies of health outcomes and events, such as hospitalizations, for a 
cohort of children with a given condition under two different scenarios—with or without NBS. 
Such analyses also assume that everything else, including treatments, is the same between groups. 
Lack of comparable data for representative screened and unscreened cohorts that are exposed to 
the same treatments following diagnosis can result in either under- or over-statement of 
differences. Accordingly, the benefits of early detection may be understated or overstated. This 
paper illustrates these common problems through a review of past economic evaluations of 
screening for two historically significant conditions, phenylketonuria and cystic fibrosis. In both 
examples qualitative judgments about the value of prompt identification and early treatment to an 
affected child were more influential than specific numerical estimates of lives or costs saved.
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1. Introduction
Newborn screening (NBS) to identify congenital disorders is a major public health success, 
saving lives and preventing disability in thousands of infants each year. Public health NBS 
programs in all higher-income countries organize the collection of dried blood spot (DBS) 
specimens on filter paper cards, have them tested in officially designated screening 
laboratories, and report the results back to health care providers [1,2]. NBS programs 
include short-term follow-up activities to ensure that children who do not pass screening 
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receive appropriate diagnostic services; some programs go further and monitor long-term 
follow-up. NBS programs constitute the largest and most widespread public health genomics 
programs, although not all NBS disorders are primarily genetic in etiology [3,4]. In addition, 
point-of-care screening of newborns for conditions such as congenital sensorineural hearing 
loss and critical congenital heart defects may be mandated or promoted by legislation or 
regulation, and public health programs can support screening and follow-up with technical 
assistance and data systems [5,6].
Governments add new disorders to NBS panels because they believe that doing so provides 
good value. The first dimension of “value” in health care is the health benefit or clinical 
utility, i.e., better outcomes for affected individuals. In health care, “value” is also 
commonly interpreted as the relative balance of health benefit and economic cost [7,8]. This 
paper suggests that although both dimensions of value are important, evidence of 
effectiveness is of primary importance. In addition, a broader definition of “value” 
encompasses all outcomes that are important to patients and their families, which includes 
the personal and diagnostic utility of genomic information—both benefits and harms—as 
well as the perceived quality of care received [9,10].
Commonly used criteria for deciding on NBS expansions include the magnitude of health 
benefits and the feasibility and costs of screening, diagnosis, and treatment [11–14]. One of 
the classical Wilson and Jungner screening criteria is that “The costs of case-finding 
(including diagnosis and treatment of patients diagnosed) should be economically balanced 
in relation to possible expenditure on medical care as a whole [15].” NBS decision makers 
typically consider cost and benefit as discrete criteria to be weighed qualitatively. Some 
decision-making bodies go further and explicitly consider the magnitude of benefits relative 
to costs using economic evaluations, e.g., cost-effectiveness [16]. Historically, however, 
most decisions on NBS expansions in the United States and Europe have not been based on 
economic criteria [16,17].
The primary focus of this paper is on how different epidemiologic methods and choice of 
data sources can lead to quite different estimates of the net health outcomes of NBS. Such 
disparate estimates in turn can lead to different conclusions regarding the magnitude of cost 
savings or cost-effectiveness. It is crucially important to assure that estimates of the effects 
of early identification are not confounded by changes in treatment patterns or differences in 
the representativeness of screened and clinically detected cohorts. Assessing outcomes is 
complex, and the reality is often more nuanced than the simple conclusions sought by policy 
makers.
This paper uses past policy decisions to screen for two historically significant conditions: 
phenylketonuria (PKU) and cystic fibrosis (CF). PKU was the first metabolic condition to be 
screened for in newborns, and decisions about initial implementation in the 1960s continue 
to influence NBS programs around the world. CF is the only NBS condition to be subjected 
to a large-scale randomized, controlled study of the effectiveness of screening and early 
treatment [13]. These salient case studies illustrate the empirical challenges in estimating 
effectiveness and cost-effectiveness in NBS.
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1.1. Economic Evaluation Overview
The balance of benefits relative to costs of an intervention or policy can be quantified using 
either cost-effectiveness analysis (CEA) or cost-benefit analysis (CBA). In CBA health 
outcomes are expressed in terms of monetary values that are intended to represent the lost 
societal welfare from premature death or incapacitation whereas in CEA health outcomes 
are calculated separately from costs. A CEA compares multiple interventions in terms of 
total outcomes and total costs. An intervention that both costs less and has better outcomes 
than the next best alternative is said to be cost-saving or dominant, and one that has better 
outcomes but the additional cost is relatively moderate is considered cost-effective.
It should be noted that cost-effectiveness is not an absolute attribute of an intervention but 
depends on the comparator. A strategy may be cost-effective in one setting compared with 
one alternative but not cost-effective in a different context or faced with a different 
comparator. Economic evaluations are based on the economics principle of the 
counterfactual, which means that everything, other than the specific intervention being 
evaluated, is held constant [18].
The first distinction among economic evaluation methods is whether the analysis models 
health outcomes (reduced deaths or disease) or just numbers of cases detected. Calculating 
the cost to detect a case tells one nothing about the value of detecting and treating the 
disease in question and hence is not informative of the balance of costs and outcomes. 
Partial CEA studies only consider costs and numbers of cases detected, whereas full CEAs 
calculate both incremental costs and health outcomes [19].
Full CEAs report whether an intervention is either cost-saving, or cost-effective, with an 
incremental cost-effectiveness ratio (ICER) that is considered favorable. Full CEAs are of 
two types: those that use “natural” measures of health, such as life-years saved, and those 
that use summary measures of health such as the quality-adjusted life-year or QALY [20]. 
CEAs that calculate incremental cost per QALY are also referred to as cost-utility analyses 
because QALYs are calculated using health utility (or health-related quality of life) scores 
for health states on a scale of 0 to 1 where 0 represents death and 1 perfect health [21]. 
Calculating QALYs for pediatric interventions such as NBS is particularly challenging [22–
24].
Whether a given ICER is considered to provide good value depends on the decision maker. 
Decision-making bodies in some countries set threshold values for ICERs or use 
benchmarks as rough guides to value, particularly in the arena of pharmaceutical coverage 
decisions. Examples of popular but arbitrary ICER thresholds include $50,000, £29,000, or 
€30–40,000 per QALY [25–27]. Alternatives to a single threshold include a range of values, 
e.g., $50,000 and $250,000 per QALY as lower and upper bounds for cost-effectiveness. 
The World Health Organization has endorsed lower and upper bounds of 1 and 3 times a 
country's per capita gross domestic product. However, the “revealed preferences” of 
decision makers in healthcare policy show that interventions with very high ICERs may be 
considered acceptable if the absolute expenditures are not too high. In particular, covered 
treatments for rare diseases, including NBS conditions, may exceed $1 million per QALY 
gained [28].
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Many policy makers outside of medicine prefer CBA estimates expressed in terms of money 
and which allow for comparison across sectors such as health, environment, and 
transportation. Cost-benefit analyses in the medical arena often rely on the traditional 
“human capital” approach to estimating the monetary value of avoided death or disability as 
the discounted present value of the stream of future annual earnings or productivity. That 
approach is problematic. First, it ignores the costs of creating and maintaining the stock of 
human capital [29]. Second, some economists have advocated a “friction cost” approach to 
valuing the loss of a worker as the temporary cost of recruiting and training a replacement; 
that approach assumes that a child death involves no loss of future productivity [30]. Third, 
the human capital approach is inconsistent with the welfare theoretic basis of modern CBA, 
also referred to as benefit-cost analysis (BCA). In particular, it excludes the value that 
society places on avoidance of pain and suffering and the spillover effects of death and 
disability on other people. Exclusion of such valuations understates the economic value to 
society of disease prevention.
Since the 1970s, the dominant approach to CBA/BCA outside of health care involves 
assessments of consumer “willingness to pay” (WTP) to value health outcomes. More 
precisely, researchers assess individual WTP to reduce by a small amount the risk of adverse 
outcomes and aggregate across individuals to value the prevention of those outcomes [31]. 
Researchers use either stated preference methods (survey data) or revealed preferences from 
real-world behavior; the latter includes estimates of compensating wage differentials in 
relation to occupational fatality risks to estimate what is referred to in the United States as 
the “value of a statistical life” (VSL). Current US regulatory agency practice uses a VSL 
estimate of roughly $9 million to value an averted death, with a range of empirical estimates 
of approximately $7 million to $11 million [32–34]. That compares with US human capital 
estimates of lifetime productivity of a little over $1 million [35]. Stated preference estimates 
of the value of preventing as statistical fatality (VPF) in Europe are lower [36].
The traditional differences between CEA/CUA and CBA/BCA studies have begun to blur, 
although those changes have not yet affected the NBS economic evaluation literature. On 
the one side, many CUA studies also report estimates of net monetary benefit calculated by 
using multiple ICER threshold values as estimates of decision makers’ WTP for health gains 
[37]. From the other side, some CBAs calculate the value of a statistical life year (VSLY) by 
dividing VSL estimates by numbers of discounted life-years and multiplying them by 
projected life-years [33]. For example, a VSL of $9 million may imply a VSLY of roughly 
$400,000 depending on the age group. VSLY or VPF-based estimates substantially exceed 
conventional WTP estimates for QALYs [27,36].
The calculation of cost-effectiveness or cost-benefit ratios can be divided in four parts. The 
first and most important component of an economic evaluation is the quantification of health 
impact. Without effectiveness in terms of better health outcomes with screening, it is 
impossible to demonstrate cost-effectiveness. Closely related to this is the calculation of the 
net economic benefits of improved health outcomes, including reduced treatment costs. The 
third component is relatively straightforward: how much does it cost to implement a policy, 
e.g., the added costs to laboratories, healthcare systems, and public health authorities to 
conduct screening, assure its quality, follow up infants, and provide diagnoses. The fourth 
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and final component is to place monetary or utility values on the health outcomes. In this 
paper, we focus on the first two components of cost-effectiveness, quantifying the gains in 
health outcomes and the magnitude of avoided costs associated with improvements in health 
outcomes.
1.2. Assessing Effectiveness in Newborn Screening
To calculate the magnitude of differences in health outcomes that can be attributed to 
screening requires the assumption of a counterfactual scenario in which the same level of 
clinical care, including treatment options, are provided for children with and without 
screening once diagnosed. Many study designs fall short of providing evidence that 
addresses this criterion. First, the “natural history” of a disorder, i.e., the prognosis in the 
absence of treatment, is misleading as a comparison, since the availability of treatment must 
be the same for NBS and non-NBS cohorts to avoid misattribution. Similarly, the use of 
historical or geographical controls for whom treatment options may have differed can be 
misleading because it is difficult to separate the impact of screening from differences in 
clinical care following diagnosis [38,39].
The basic approach to assess net health impacts of NBS in principle is straightforward: 
compare health outcomes of affected children of the same ages who differed with regard to 
the timing and type of diagnosis, but were given the same treatments once diagnosed. 
Specifically, researchers should seek to produce evidence that early versus late diagnosis is 
associated with markedly better health or developmental outcomes at the same chronological 
age. This last point is crucial. It is common that infants diagnosed presymptomatically with 
a genetic disorder based on NBS or family history are healthier at the time of diagnosis than 
those diagnosed at a later age based on the appearance of symptoms [40,41]. Such findings 
tell us nothing about the effectiveness of early diagnosis in avoiding the subsequent 
development of symptoms.
Evidence of effectiveness may come from prospective follow-up of screened and unscreened 
cohorts for a range of endpoints, which may include survival, avoidance of severe 
morbidity, and retention of normal neurological function versus intellectual disability. 
However, long-term outcomes in screened cohorts are generally not available when 
conditions are being considered for inclusion in NBS panels. Instead, researchers may have 
data on outcomes among a group of children with a disorder who were diagnosed at various 
ages. Early diagnosis may occur as a result of a positive family history, typically the 
experience of an affected older sibling, or through prenatal or neonatal screening. Analysts 
can stratify their data by age of diagnosis to assess outcomes for early versus late diagnosis. 
However, it is important to compare outcomes at the same ages in order to avoid bias from 
age differences in the progression of symptoms. In particular, if outcomes get worse as 
children get older, children diagnosed as infants will appear healthier than children 
diagnosed later, on the basis of symptoms, even if there were no effect of early diagnosis.
Another potentially valuable source of information on the impact of early versus late 
diagnosis is paired sibling cohort studies. Such studies follow cohorts of affected children in 
which an older sibling was detected based on symptoms and a younger sibling was detected 
based on testing, usually as a result of the positive family history. One can compare 
Grosse Page 5
Healthcare (Basel). Author manuscript; available in PMC 2015 December 21.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
outcomes for the siblings at the same age group. One limitation is small numbers; small 
differences in absolute magnitude are unlikely to be statistically significant even if large in 
relative size and clinically important. Investigators who follow conventional or frequentist 
statistical inference will often dismiss such findings as evidence of no association. However, 
that is an error of statistical inference. Lack of conclusive evidence of effect is not 
equivalent to evidence of no effect. All that one can conclude from such an analysis is that it 
is not possible to precisely estimate the magnitude of effect, if any. It is important to 
compare new findings with previous findings in terms of the direction and relative 
magnitudes of association to look for consistency.
It is difficult to reliably ascertain long-term health outcomes for unscreened cohorts. One 
reason is that in the absence of screening, individuals with a given congenital or genetic 
condition may not necessarily come to clinical attention. That may happen because in some 
cases the disorder is subclinical, symptoms are nonspecific, or the condition results in early 
death without postmortem diagnosis. Another reason is that most conditions detected by 
NBS are rare; to identify sufficient numbers of cases to assess outcomes may require 
collecting outcomes data for cohorts based on millions of births, which may be impractical. 
Furthermore, outcomes for historical cohorts, who did not have access to currently available 
treatments, typically are worse than expected outcomes with current treatments in the 
absence of screening [38,39].
Data limitations have important implications for the conduct and interpretation of economic 
evaluations. On the one hand, extrapolation of data from historical controls to the projection 
of outcomes in the absence of NBS can substantially overstate the health and economic 
impacts of NBS. Not only may controls lack access to the same interventions following 
diagnosis, but trends in health outcomes resulting from improved treatments reduces the 
magnitude of potential health gains from early detection. On the other hand, lack of long-
term follow-up data can lead to the understatement of future health and economic benefits. 
For example, higher economic productivity resulting from improved child health and 
nutrition is difficult to model and is often left out of analyses. As a result, estimates of net 
economic benefit may understate the actual benefits.
2. Case Studies
2.1. Phenylketonuria (PKU)
PKU is an autosomal recessive disorder which, without treatment, results in intellectual 
impairment and disability. Prior to the development of dietary treatment for PKU in the 
1950s, as many as 95% of individuals with PKU developed severe to profound intellectual 
disability (with IQ < approximately 50), almost all of whom received residential care [42]. 
According to a later study, about 95% of untreated individuals with PKU had below normal 
intelligence, with about 80% in the severely to profoundly affected range [43]. During the 
mid-1950s, low-phenylalanine dietary treatment was developed and shown to be highly 
effective in preventing further progression of cognitive decline and to prevent the onset of 
decline when begun in early infancy among younger siblings of affected children [44,45]. 
Beginning in the late 1950s, a urine test for PKU was widely used in the United Kingdom to 
screen infants for PKU during home visits [46].
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In 1960, Robert Guthrie developed a highly sensitive and inexpensive semiquantitative 
bacterial inhibition assay to screen for PKU in DBS that could be used in birthing hospitals. 
A screening study Guthrie conducted among 3,118 residents of the Newark (New Jersey) 
State School in 1961 found that 21 had PKU [47]. Following a large-scale pilot screening 
study in 29 US states, NBS for PKU was quickly adopted in most US states between 1963 
and 1967 [46,48]. The rationale was the opportunity to avoid preventable severe disability 
and provide children and their families with the opportunity of healthy, independent 
development.
A frequent argument made by advocates of screening newborns for PKU was that it would 
save taxpayers money by reducing the money spent by states on residential institutions [46]. 
Subsequently, analysts compared the expected reduction in costs resulting from avoided 
institutionalization with the cost of screening and treatment [49–52]. In California, detailed 
cost calculations from the first 2 years of screening showed that the cost per child with PKU 
detected was $2500 and the cost of dietary treatment for 10 years was approximately $8000 
[49]. In comparison, the expected cost of institutionalization over a 30 year period was 
estimated to be $162,000, for a cost-savings ratio of 15:1. In Canada, Webb suggested that 
the cost to diagnose and treat one child with PKU for 5 years was $7000, compared with an 
expected cost of $250,000 to provide lifetime institutional care, a ratio of 36:1 [51].
Other analyses also concluded that screening for PKU would save money, albeit not as 
dramatically. Steiner and Smith, using data from Mississippi, concluded that screening and 
treatment for 7 years would cost $56,000 per child with PKU and the avoided cost of 
institutional care over a 30-year period would be $77,000 per child, a ratio of 1.4:1 [50]. In 
addition, the authors calculated a benefit-cost ratio, including gain in lifetime productivity as 
a benefit, of 2.6:1. Van Pelt and Levy used Massachusetts data on screening for PKU and 
several other metabolic conditions, and reported a cost-savings ratio of 1.8:1; they assumed 
that just 4 of 7 children with PKU would have required lifetime institutional care [52]. 
Subsequent economic analyses, whether reported as CEAs or CBAs, have also concluded 
that screening for PKU is cost-saving or cost-beneficial because of its prevention of severe 
disability [53–61]. For example, in a 2005 CEA study, Geehoed et al. projected that 64% of 
children with PKU would experience severe intellectual disability in the absence of NBS, 
citing two studies reporting data on children or adults with untreated PKU born in the 1950s 
or earlier [61].
CBAs of PKU screening have relied on the “human capital” approach to estimating the 
monetary value of avoided death or disability as the discounted present value of the stream 
of future annual earnings or productivity in addition to avoided costs of institutional care. 
According to the “friction cost” approach there is no loss of productivity attributable to 
congenital conditions [30]. Economic analyses of the expected benefits of screening for 
PKU, although they appear to have been persuasive, were not based on counterfactual 
comparisons of screened and unscreened cohorts exposed to dietary treatment. Analysts 
assumed that the natural history of untreated PKU was the appropriate comparison. They 
therefore used case series of untreated individuals with PKU as the comparison with cohorts 
of screened children with PKU. It was widely assumed that children with PKU who are not 
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treated soon after birth would develop irreversible severe cognitive impairment and require 
lifetime institutional care [46].
However, published data available in the late 1960s and early 1970s belied the assumption 
that late-diagnosed, late-treated children with PKU have the same prognosis as untreated 
individuals. Specifically, peer-reviewed studies found that many late-treated children had 
cognitive test scores either in the low-normal range or had scores indicative of mild 
intellectual disability [62]. For example, two studies published in 1968 both reported that US 
or UK children who were put on a low-phenylalanine diet after 4–6 months of age had mean 
IQ scores of 69 or 77, respectively [63,64].
Experts on PKU came to realize that early cognitive deficits in late-diagnosed PKU with 
prolonged treatment can be partially reversed in many cases [65,66]. In California, adults 
with PKU who were born after 1965, but were not detected through NBS, had mean IQ 
scores of 76 if diagnosed at 3–7 years of age, 92 if diagnosed at 1–2 years of age, and 96 if 
diagnosed and treated at any time in infancy [62,65]. Despite this recognition among PKU 
clinical specialists, the NBS community and policy analysts continue to cite obsolete 
estimates of economic benefits that were predicated on the invalid assumption that late 
treatment is equivalent to no treatment. A CEA study published in a major peer-reviewed 
journal in 2006 assumed that in the absence of NBS, 95% of children with PKU would 
experience moderate to severe developmental delay [60].
Screening for PKU may be less likely to be cost saving (in terms of direct costs) than was 
previously calculated for a few other reasons [16,67]. First, classical PKU is now recognized 
to be the severe portion of a spectrum of hyperphenylalaninemia, and a large percentage of 
infants detected as abnormal by the Guthrie test have mild hyperphenylalaninemia and do 
not benefit from treatment [68]. Second, the per-person cost of treatment for PKU is now 
much greater than was assumed previously, when it was thought that older children could 
safely discontinue the unpleasant, arduous, and expensive low-phenylalanine diet. Since the 
early 1980s, it has been recommended by experts that dietary therapy be pursued for life 
[46]. Third, individuals with intellectual disability are now much less likely to be 
institutionalized than was the case historically, resulting in substantially lower direct costs of 
care.[69,70]. Fourth, children born to mothers with inadequately treated PKU (maternal 
PKU) are at risk for birth defects and disability. With NBS, more women with PKU have 
offspring at risk of maternal PKU and the associated costs of lifetime care [71].
On the other hand, the full benefits to society of screening newborns for PKU in avoiding 
disability and promoting optimal human development could be even larger than previously 
estimated. In particular, the economic benefits from improved labor productivity due to 
gains in cognitive ability are large, even for those who would not be classified as disabled. It 
has been estimated that each 1 IQ point gain raises lifetime earnings by thousands of dollars 
[72]. Similar methods have been used to evaluate the economic benefit of prevention of 
iodine deficiency from the societal perspective [73]. However, direct stated preference 
estimates of WTP to avoid a 6-point loss of IQ in a child are much smaller than the human 
capital estimates based on expected gains in lifetime earnings [74].
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Studies are also needed to quantify other impacts of prompt versus late treatment of PKU 
such as psychosocial health impacts that can be quantified in terms of QALYs. CUAs of 
other NBS conditions that result in neurodevelopmental disability have adopted widely 
varying estimates of utility weights for the calculation of QALY gains from prevention of 
neurological problems, which calls into question the reliability of the QALY estimates [23].
2.2. Cystic Fibrosis (CF)
2.2.1. Health Outcomes—Cystic fibrosis is an autosomal recessive disorder caused by 
mutations in the CFTR gene that is most common in populations of European ancestry. It is 
a multisystem disease that primarily affects the gastrointestinal and respiratory systems and 
if not treated typically causes death in childhood from progressive lung disease following 
recurrent bacterial infections with organisms such as Pseudomonas aeruginosa. 
Approximately 15%–20% of newborns with CF have meconium ileus (MI), an intestinal 
obstruction present at birth that generally requires surgery to correct and is typically 
associated with worse outcomes. Most individuals with CF develop pancreatic insufficiency 
which can cause malnutrition and growth failure.
With improved treatments, most notably in diet, pancreatic enzymes, and nutritional 
management as well as antibiotic treatments, survival has increased dramatically in high-
income countries [75]. For example, median predicted survival increased between 1986 and 
2008 from 20.1 to 35.2 years in the Republic of Ireland and from 26.7 to 37.4 years in the 
United States [76]. In Canada, using a different method, median survival age was calculated 
to have increased from 31.9 years in 1990 to 49.7 years in 2012 [77]. In Australia, yet 
another measure, mean age at death, increased from 13.3 years in 1979 to 26.6 years in 2005 
[78]. There appear to be differences across countries in CF survival, but it is difficult to 
compare because of the calculation of non-comparable measures [79]. Less dramatic 
improvements in lung function have also been reported [80].
Screening newborns for CF using DBS was first implemented in the early 1980s in New 
Zealand, and portions of Australia, the United States, France, and Italy. A meeting held by 
the US CF Foundation in 1983 concluded that there was insufficient evidence to warrant 
screening [81]. Two randomized controlled trials (RCTs) of CF NBS were initiated in the 
mid-1980s, one in Wisconsin in the United States and one in the United Kingdom, the only 
such trials of NBS that have been conducted for any NBS disorder [82]. It is unlikely that 
more RCTs of NBS tests will be conducted in the future. Each of the RCTs had limitations. 
The published analysis of the UK study [83] had incomplete ascertainment of unscreened 
children [84] and was excluded from a Cochrane review [85]. The Wisconsin RCT also had 
disadvantages, including unmatched study arms and the possible alteration of health 
outcomes in the non-NBS arm due to close clinical monitoring, both of which likely biased 
comparisons to the null, i.e., no difference in outcomes [86,87].
The Wisconsin RCT yielded evidence of nutritional and growth benefits [85,86], although 
the lower quality UK RCT did not [83]. Observational studies were also conducted in 
several countries where screening had been adopted in some places and not others. In 1996, 
an expert workshop convened by the US Centers for Disease Control and Prevention (CDC) 
and the US CF Foundation concluded that although there was RCT evidence of nutritional 
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benefit more evidence was needed and called for collection and analysis of additional data, 
including pilot studies with research protocols [88].
Between 1998 and 2003, several US states started routine screening for CF; one of which, 
Massachusetts, added screening for CF with parental consent. The British government made 
a political decision in 2001 to start screening for CF in England and Wales, despite an 
unfavorable commissioned evidence review [3]. France made a decision in 2002 to screen 
all newborns for CF, with parental consent, but did not commission an evidence review until 
years later [89]. The Netherlands took a different approach. A Health Council of The 
Netherlands systematic evidence review on proposed NBS conditions released in 2005 
concluded that screening for CF would be of borderline benefit and called for additional 
studies [90]; the decision to adopt CF NBS followed in 2010 [91].
The CDC and CF Foundation held another expert workshop on CF NBS in 2003. The result 
of that meeting and a subsequent evidence review was that there was now sufficient 
evidence of “moderate” benefit to justify adding CF to NBS programs [84]. Analyses of 
outcomes of CF NBS generally exclude children with MI from both screened and 
unscreened cohorts. The strongest evidence of benefit was in improved nutritional status 
(growth) following the use of pancreatic enzyme supplements and close attention to feeding 
practices. Two other patient-oriented outcomes were also considered to have fairly strong 
evidence: improved child survival to age 10 years and better cognitive development among 
the subset of children at nutritional risk. The CDC report concluded that no consistent 
evidence of benefit had yet been established for other CF outcomes, including lung function, 
respiratory infections, health-related quality of life, as well as use and costs of medical care 
[84].
CF was subsequently added to a recommended uniform screening panel that was adopted by 
a US advisory committee in 2005 [92]. By 2009 all US states had implemented screening for 
CF. Canadian provinces followed the US lead beginning in 2007 and by 2015 all but one 
province, Quebec, screened for CF [1,93,94]. In contrast, in 2011 just 9 countries in Europe 
screened for CF nationwide, compared with 33 countries screening for PKU [2], an increase 
from just 2 countries in 2004 [95].
One reason for the relatively uneven adoption of CF NBS in high-income countries, 
compared with PKU, is the relatively modest benefit from early detection of CF. Until very 
recently, CF therapies generally only slowed the rate of decline in function rather than 
restoring normal function. Children with CF detected by NBS typically develop recurrent 
lung infections and progressive lung disease beginning in early infancy [96,97]. 
Furthermore, there is a lack of documented evidence that survival or lung function are better 
in countries with CF NBS than in those without screening. In comparison, differences in 
treatment practices across countries and centers unrelated to NBS can result in large 
differences in the magnitudes of clinical outcomes in CF [98,99].
In particular, evidence of improved lung function in cohorts of children with CF detected by 
NBS is equivocal, as noted above [84]. This is in spite of consistent evidence of improved 
growth with NBS and evidence that better nutritional status in children with CF predicts 
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better lung function as well as survival [100–102], but nutrition is just one of many factors 
affecting lung function [103]. Neither of the two RCTs of CF NBS found evidence of 
pulmonary benefit [39,83–85]. Children in the NBS arm of the Wisconsin RCT had higher 
rates of P. aeruginosa infection because of earlier exposure to older patients with CF until 
care protocols were modified [103].
Evidence from observational studies on pulmonary outcomes in relation to age and type of 
diagnosis is mixed and subject to potential biases. An Australian study that used historical 
controls born during the years prior to the introduction of NBS reported better lung function 
in a NBS cohort [104,105], although the use of historical controls has the disadvantage of 
potential bias resulting from temporal changes in standards of care [39]. A small non-DBS 
screening study in The Netherlands during 1973–1979 found less decline in lung function in 
contemporaneous screened children [106], but at least two other studies in different 
European populations did not find differences [107,108]. One US study that compared 
children in the same state who were born in hospitals that either did or did not screen for CF 
found that lung function was initially similar between the NBS and non-NBS cohorts but 
diverged over time different in favor of the NBS cohort and became significant by age 15 
years [109]. One sibling comparison study published in 1977 found significantly better lung 
function in screened children [110]. Three later sibling studies did not find statistically 
significant differences in childhood [111–113], but one of the studies did find a significant 
difference in adults [113].
Several analyses of data from the US CF Foundation Registry (CFFR) have reported 
significantly improved lung function for children with diagnosis through NBS compared to 
those detected symptomatically [40,80,98]. However, these findings may be a statistical 
artifact of how diagnosis was assigned in the registry. As this author has previously pointed 
out, the CFFR classifies all children who were symptomatic (excluding MI) at the time of 
diagnosis as diagnosed based on symptoms, even if they had been detected by NBS prior to 
diagnosis [39]. The implication is that children detected by NBS who are symptomatic at 
birth are assigned by the CFFR to the symptomatic detection group rather than to the NBS 
group. The exclusion of symptomatic children from the NBS diagnosis group in the CFFR 
could make the NBS group appear to have better outcomes even if there were no causal 
effect of early diagnosis. That hypothesis is consistent with the finding in one study that 
children detected as a result of prenatal diagnosis—none of whom were assigned in the 
CFFR to the symptomatic diagnosis group—were found to have no significant advantage in 
lung function, unlike the NBS group [40].
As noted above, one of the most salient potential benefits of CF NBS from a population 
health perspective is improved survival [84]. Mortality reductions can be modeled in either 
absolute or relative terms. Formerly, child mortality was common in CF, and older studies 
often reported large absolute differences in survival with NBS. A meta-analysis of non-US 
studies reported cumulative death rates by age 10 years of 0.6% in screened and 9.6% in 
unscreened cohorts [87]. That meta-analysis included data from a follow-up study to UK 
RCT in which investigators reviewed registry and death certificate data to identify CF-
related deaths up to age 5 years, including among unscreened children who were not 
ascertained in the original study. No deaths were reported among 78 children in the screened 
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group without MI compared with 4 (5.6%) CF-related deaths before 5 years of age among 
71 unscreened children without MI (p < 0.05) [114].
Sharp drops in child mortality with improvements in CF treatments in recent decades have 
greatly reduced the number of deaths that can potentially be avoided through early detection 
by NBS [115]. For example, the Wisconsin trial reported no deaths below age 10 years 
among the small numbers of enrolled children who did not have MI [87]. A state-level 
analysis of CFFR data for survival among children with CF born during 1986–1991 found a 
1.7 percentage point difference in mortality through age 9 years in states with and without 
CF NBS, 0.65% versus 2.35%, or a relative reduction of 72% [87]. That finding was not 
statistically significant but is consistent with improved survival, albeit not precisely 
estimated. The authors acknowledged that differences in quality of care between states 
might have contributed to the difference between states in CF child deaths. An individual-
level analysis of CFFR data also reported that children detected in the first month of life 
without MI had significantly improved survival regardless of whether they were classified 
with screening (NBS or prenatal) or symptomatic diagnosis [116].
One study suggests that a survival advantage of CF NBS may extend into adulthood [105], 
although this requires replication. In the Australian historical cohort study discussed above, 
a statistically significant survival advantage at 10 years, which was attenuated at age 15 
years [87], became stronger at 25 years follow-up [105]. Specifically, 61% of the pre-NBS 
cohort had either died or undergone lung transplant by age 25, compared with 34% of the 
NBS cohort. Both cohorts had relatively unfavorable outcomes compared with a Dutch 
study of 52 sibling pairs with CF which reported that 3 older siblings versus 1 younger 
sibling died prior to age 25 and 2 vs. 0 underwent lung transplants [113]. Slieker et al. 
concluded that a p value of 0.21 for the first comparison indicated “no differences” in 
survival [113]. However, the absence of a statistically significant difference is not evidence 
of no difference; the findings are consistent with a large relative reduction in mortality with 
early detection.
2.2.2. Economic Evaluations—Published or publicly disseminated systematic evidence 
reviews and health technology assessments of adding CF to NBS panels did not include 
estimates of cost-effectiveness owing to a lack of published full CEAs at the time reviews 
were prepared. The Alberta HTA program in 2007 undertook a review of published 
economic analyses of CF NBS and prepared their own calculations of the cost of 
implementation [117]. The Washington State Department of Health constructed a CBA 
model of CF NBS in 2004–2005 which projected a benefit-cost ratio of at least 4 to 1, 
assuming a child mortality reduction of 1–2 percentage points[118] that was consistent with 
subsequently published US estimates [87]. That CBA was essential to the policy decision in 
Washington State to add CF to their NBS panel.[16] Although that analysis was never 
officially released, it is discussed in a forthcoming paper.
Three full CEAs of NBS for CF have been published in English [119–121], along with one 
partial CEA [122] that calculated net costs but did not quantify health outcomes. Several 
other English-language partial economic evaluations of CF NBS have been published. Two 
decision analyses compared the costs associated with different NBS protocols to identify the 
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most efficient screening strategies [123,124]. Two other studies assessed costs associated 
with CF NBS and diagnostic tests in Wisconsin [125,126]. All four of the CEA studies 
estimated that at least one screening strategy would be cost-effective relative to no screening 
[119–122]. However, there were disagreements among the studies as to which screening 
strategy would be most cost-effective, what outcomes would be improved, and by how much 
treatment cost would be reduced.
A recent cost accounting study from Wisconsin estimated the total added cost of CF NBS, 
including diagnostic testing, be about $7 per infant tested for an algorithm using molecular 
genetic testing as a second-tier screen [123]. The Dutch CEA studies assumed similar 
incremental costs of screening, somewhat lower for strategies not using molecular testing 
largely because of the high assumed cost of genetic counseling [121].
The first CEA study, from the United Kingdom, was the only one which projected QALY 
gains rather than life-years gained. The study optimistically assumed that screening would 
delay the onset and progression of CF respiratory symptoms by an average of 6 months, 
thereby resulting in better lung function and health-related quality of life, modeled based on 
lung function [119]. These assumptions were adopted despite the authors’ acknowledgement 
of a lack of supporting evidence. In addition, it was assumed that screening would sharply 
reduce costs of treatment. On the basis of those optimistic hypothetical assumptions, 
including a relatively low cost of screening, it was calculated that screening would be highly 
cost-effective, with an ICER <£7000 per QALY gained [119]. To calculate QALY gains 
from NBS Simpson et al. [119] compared an average utility weight of 0.75 for a sample of 
patients with symptomatic CF to an arbitrary value of 0.95 for asymptomatic patients. 
However, the internal comparison of data for UK patients with CF showed relatively small 
differences in utility weights for patients with varying levels of lung function [127].
Two subsequently published CEA studies assumed improved survival with NBS but no 
differences in treatment costs, lung function or health-related quality of life. The authors of 
the two studies assumed 25% relative and 1.5% absolute reductions in cumulative child 
mortality with 94% of infants with CF assumed to survive to age 6 years in the absence of 
NBS [120,121]. Both studies projected that certain screening approaches for CF would 
likely have an ICER < €30,000 per life-year gained and would therefore be considered cost-
effective. If treatment costs were reduced with early diagnosis, it was concluded that 
screening might even be cost-saving [121]. However, the absolute mortality assumption in 
the two studies does not appear to be consistent with data from The Netherlands. According 
to registry data, roughly 98% of infants with CF born in The Netherlands during 1990–1994 
survived to age 6 years, without NBS [128]. Consequently, the validity of the ICER 
estimates of the two studies is unclear.
One partial CEA study from Quebec, Canada, calculated total costs and numbers of cases of 
CF detected, and projected that total costs would be lower with NBS. The authors stated that 
screening dominates no screening, i.e., is cost-saving with better health outcomes, although 
they did not calculate health outcomes. Nshimyumukiza et al. assumed, based on an 
unpublished analysis of provincial hospital statistics, that average costs of hospital care 
would be almost 85% lower for children identified through NBS [122]. In contrast, the 
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Washington CBA study assumed a more modest reduction of one hospitalization per child 
detected by NBS, equivalent to a roughly 25% lower hospitalization cost [118].
Several studies have reported reduced costs of hospital care with CF NBS [95]. First, the 
published analysis of data from the UK RCT reported 30% fewer hospital days during 
infancy for infants detected by screening than infants born in the same area who were 
diagnosed clinically [83]. However, because there was incomplete ascertainment of cases in 
the clinical cohort and infants with mild cases of CF were likely not ascertained, the 
comparison may be biased in favor of the NBS cohort. More importantly, the higher quality 
Wisconsin RCT, which had complete ascertainment and follow-up, found no difference in 
hospital costs for children with CF in the two study arms [123,126].
Findings from observational data, unlike the Wisconsin RCT, indicate lower hospitalization 
costs in CF NBS cohorts. The Australian historical control study and the French study that 
compared two neighboring regions both reported significantly fewer hospitalizations in the 
NBS cohorts [108,129]. Further, a UK registry study found that average treatment costs 
were lower by 21%–35% for children aged 4–9 years who were diagnosed through NBS in 
Scotland than those living in England, which at the time did not have a country-wide CF 
screening program [130]. However, geographic comparisons do not control for potential 
differences in care practices between regions with and without NBS programs. An analysis 
of individual-level US CFFR data also reported that fewer children classified as diagnosed 
by NBS were hospitalized in infancy [40], but as noted above infants detected through NBS 
who were symptomatic were excluded from the NBS group.
The cost-effectiveness of NBS for CF is also influenced by other economic assumptions. 
One is the avoidance of costs associated with the “diagnostic odyssey” (repeated 
examinations and laboratory tests and acute care visits to treat symptoms) entailed in 
reaching a definitive diagnosis of CF in the absence of NBS. Two CEAs assumed that 
reduced diagnostic costs would offset 16%–36% of the cost of screening [119,120]. 
However, estimates of the healthcare costs associated with CF diagnosis in the absence of 
NBS are variable. An audit of UK costs for 25 children with CF suggests cost < £1000 
[119]. A more comprehensive audit of 36 Dutch patients yielded an equivalent cost estimate 
of approximately €9000 [120].
The first Dutch CEA calculated through a sensitivity analysis that two additional 
assumptions could make screening cost-saving (negative total cost).[120] First, they 
calculated that a reduction in the ordering of sweat tests, similar to that which was reported 
in Wisconsin following the introduction of screening for CF [125], could offset almost 40% 
of the added cost of screening. Second, if NBS were to lead to 30% fewer births affected by 
CF, NBS for CF would be cost-saving. However, preliminary findings from France of a 
lower birth prevalence of CF attributed to NBS [131] were not supported by a subsequent 
report, nor by subsequent studies from other countries [132,133].
The recent Dutch CEA incorporated the assumption of a large reduction in ordering of sweat 
tests into the base-case model rather than as a sensitivity analysis [121]. This assumption 
was crucial to their conclusion that CFS NBS would be cost-effective, with an ICER < 
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€30,000 per life-year gained. If no reduction in sweat tests was assumed to occur, the ICER 
would be approximately €75,000 per life-year gained and screening would not be considered 
cost-effective. Conversely, if the number of sweat tests decreased by 90% with NBS, other 
things constant, screening would likely be cost-saving [121].
3. Discussion
Estimates of cost savings or cost-effectiveness of NBS are necessarily dependent on 
quantitative estimates of effectiveness derived from clinical and epidemiologic research. 
Screening per se does not improve outcomes; it is the interventions that are enabled by early 
diagnosis that alter outcomes. Therefore, cost-effectiveness is crucially a function of the 
effectiveness of available therapies. An obvious difference between PKU and CF is that 
PKU has a highly effective therapy, which can virtually eliminate the most important 
adverse health outcome of the untreated disorder, whereas CF currently does not. An 
important determinant of the reliability or robustness of CEA estimates is the quality and 
consistency of epidemiologic evidence of effectiveness [134,135]. Although there is a high 
confidence in the nutritional benefits of CF NBS, estimates for other outcomes are less 
certain. Given that ICER estimates rely on assumptions of non-nutritional benefits, including 
reductions in diagnostic and treatment costs as well as survival, the robustness of published 
CEA estimates for CF NBS can be considered to be relatively low. The implication is that 
more research is needed to provide more robust estimates of outcomes of CF NBS, in 
particular survival and hospitalization costs, to inform future economic evaluation studies.
Cost-effectiveness is also crucially dependent on the extent to which the therapeutic 
effectiveness varies with the age at which treatment is begun. If a disorder has a therapy that 
is effective when it is initiated, even if the diagnosis is delayed, the effectiveness and cost-
effectiveness of NBS will be lower than if it is essential for the treatment to be administered 
during a presymptomatic period in order to be effective. Demonstrating positive outcomes 
through long-term follow-up of a screened cohort is not sufficient to quantify the 
effectiveness of NBS and early treatment; one must also have comparable long-term 
outcome data for late, symptomatically diagnosed individuals who received standard-of-care 
treatment once diagnosed. It is the difference in the outcomes of the two groups that 
determines the magnitude of effectiveness of early detection.
When NBS for PKU was established, it was believed that in order to avoid severe, 
irreversible intellectual disability it is essential to begin dietary therapy within the first 
months of life. That, combined with the practice at the time of routine institutionalization of 
persons with intellectual disability, made the economic argument for NBS very compelling. 
Even though there is now good evidence that progressive cognitive deterioration in children 
with unscreened PKU can be halted and in many cases even partially reversed with dietary 
treatment following diagnosis [62], the value proposition for PKU NBS is still highly 
compelling. Early initiation of treatment and maintenance of effective dietary control of 
blood phenylalanine following NBS has been shown to make a large difference in ultimate 
cognitive and behavioral outcomes for individuals with PKU, although research on newer, 
more effective treatments is ongoing [136]. However, outcomes in many cases are not 
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optimized, and barriers to accessing treatments for adults with PKU remain a serious issue 
[137].
Previously calculated economic benefits of PKU NBS may now be substantially lower, 
owing to different patterns of care, the partial reversibility of cognitive impairment in many 
cases, even with late initiation of dietary treatment, and higher costs of dietary treatment. On 
the other hand, economic benefits that were not previously taken into account, such as 
impacts of reduced cognitive ability short of overt disability on economic productivity, 
could be included. Updated estimates of the magnitude of cost savings and benefit-cost 
ratios for PKU NBS are needed. However, it is challenging to quantify the number of IQ 
points gained per individual with PKU, as well as the monetary value of an IQ point, and it 
is even more challenging to measure and value other endpoints, such as executive function.
One factor that could potentially affect calculations of the cost-effectiveness of NBS for 
condition such as CF is consideration of the impact of the detection of ambiguous cases or 
cases that may develop clinical symptoms at some point years in the future. Infants with 
abnormal CF screening results and inconclusive confirmatory testing results are referred to 
as having “CFTR-related metabolic syndrome” or CF screen positive, inconclusive 
diagnosis” (CFSPID) [138]. Indeterminate or equivocal diagnoses can impose costs on the 
healthcare system and families, which have not been estimated or included in any of the 
published CEAs. Research is needed to understand the long-term health and economic 
consequences of the clinical follow-up of children with equivocal diagnoses.
Quantifying the cost-effectiveness and cost-benefit of screening for CF is particularly 
challenging, despite a large number of empirical studies reporting long-term outcomes in 
both screened and unscreened cohorts. The nutritional benefits of early detection and 
treatment of CF are well established, but it is hard to quantify the direct benefits of better 
nutritional status. Higher percentiles of height-for-age and weight-for-age have been shown 
to predict better lung function as children age [100]. That might account for the finding 
reported in some studies that children with CF detected by NBS had significantly less 
deterioration in lung function over time [106,109]. Better nutritional status has also been 
reported to predict better health-related quality of life among children ages 9-19 years 
participating in the Wisconsin study [139].
More research is needed to better quantify the long-term health benefits of CF. One 
challenge is that since child mortality in CF is now rare in high-income countries, it is less 
salient and much harder to estimate with precision. Nonetheless, it is important to confirm 
previous US estimates based on comparisons of 10-year CF survival rates for states that 
were or were not screening for CF prior to 1996 [87] using more recent data to assess 
outcomes in states that began screening between 1998 and 2003. In addition, fixed effects 
statistical analyses that compare hospitalization costs in US states or Canadian provinces for 
infants and young children with CF based on the timing of adoption of CF NBS and 
controlling for pre-existing geographic differences in care patterns could be informative.
The quantification of the health benefits of NBS for specific disorders is desirable. However, 
in many countries, including the United States, decisions on whether to add disorders to 
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NBS panels appear to be primarily qualitative, based on evidence of avoidance of severe 
morbidity or mortality along with considerations of perceived test accuracy, feasibility, and 
affordability [16]. The US Advisory Committee on Heritable Disorders in Newborns and 
Children currently contracts evidence reviews for candidate disorders [140]. As part of that 
process, decision analytic models are set up to quantify expected health outcomes [141]. 
However, the published evidence-base for candidate disorders is often insufficient to support 
meta-analyses of health outcomes. In any case, the decision matrix used by the Committee 
to make recommendations is qualitative. The historical case studies of the US adoption of 
PKU and CF NBS, both of which predated the current decision-making matrix, are also 
consistent with the dominance of qualitative assessments of clinical benefit in the decision-
making process for NBS panels.
In jurisdictions in which health policy decisions are based in part on explicit considerations 
of cost-effectiveness, the quantification of effectiveness may be more critical. However, the 
limited salience of the quantification of benefits and cost-effectiveness in NBS decision 
making appears to be true in many other countries, even those in which cost-effectiveness is 
officially listed as a criterion. An analysis of 22 NBS expansion decisions in European 
Union member countries found that just two (9%) were accompanied by quantitative meta-
analysis of evidence of benefit and just four (18%) were informed by CEAs [17]. Three of 
the 22 decisions were made by the UK National Screening Committee, for CF, sickle cell 
disease, and medium-chain acyl-CoA dehydrogenase deficiency screening in England [142]. 
Previous publications have discussed the policy decisions for CF and sickle cell disease 
screening in England, including the limited influence of CEA calculations [143,144].
4. Conclusions
In conclusion, attempts to assess the effectiveness of NBS in improving health outcomes 
constitute a critically important part of the process for deciding which conditions should be 
added to NBS panels. Such assessments can be both quantitative and qualitative. If 
information is available to quantify both health outcomes and short-term and long-term 
costs, economic evaluations can also be undertaken even if cost-effectiveness or cost-benefit 
are not treated as formal criteria for expansion of NBS panels. Such analyses should be 
regarded as preliminary in nature and should be revisited in the future once more complete 
information becomes available. Although that would be too late to inform policy decisions 
on adding NBS disorders, the information might be of use to other jurisdictions considering 
NBS expansions.
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